North America: Food, Drugs, Healthcare, Life Sciences

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.

Of the emerging litigation topics across America, one of the more burdensome on our judicial system involves PFAS, or per- and polyfluoroalkyl substances.

Independent pharmacies are facing a new level of scrutiny—and this time, it's coming directly from a major pharmaceutical manufacturer.

On May 12, 2025, President Trump signed the second drug pricing-related Executive Order (EO) of his current administration. While President Trump's first drug pricing-related EO...

Nineteen states plus the District of Columbia filed a federal Complaint in U.S. District Court for the District of Rhode Island on May 5, 2025 alleging that the Trump Administration's recent activities...

Contractual relationships thrive on certainty. Yet the far-reaching scope of tariffs imposed and deferred over the last several months has raised concerns that businesses...

In 2024, Osler represented 160 clients on preferred share financings — more than in any other year reflected in the Deal Points Report. Notwithstanding this data point...

Of the emerging litigation topics across America, one of the more burdensome on our judicial system involves PFAS, or per- and polyfluoroalkyl substances.

Independent pharmacies are facing a new level of scrutiny—and this time, it's coming directly from a major pharmaceutical manufacturer.

On May 12, 2025, President Trump signed the second drug pricing-related Executive Order (EO) of his current administration. While President Trump's first drug pricing-related EO...